Broadwood Partners, L.P.'s Form 4 filing
Lineage Cell Therapeutics, Inc. (LCTX) · filed Jan 28, 2025
- Accession no.
- 0000919574-25-000555
- Filed
- Jan 28, 2025, 7:49 PM ET
- Trade date
- Jan 27, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market purchases total $6.00M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Broadwood Partners, L.P.CIK 0001278386 | Director, 10% Owner |
| Bradsher Neal CCIK 0001278388 | Director, 10% Owner |
| Broadwood Capital IncCIK 0001278387 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 27, 2025 | Common Shares | PPurchaseAcquired | +7,894,737 | $0.76F2 | +$6,000,000.12 | 49,560,992 | Direct | |
| Jan 27, 2025 | Common Shares | PPurchaseAcquired | 0 | $0.00 | $0 | 49,560,992 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
On November 19, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Lineage Cell Therapeutics, Inc. (the "Issuer") pursuant to which Broadwood Partners agreed to acquire (i) 7,894,737 of the Issuer's Common Shares, no par value (the "Common Shares") and (ii) 7,894,737 common share purchase warrants (the "Common Warrants"), each of which will be exercisable for one Common Share, from the Issuer in its registered direct offering for a total purchase price of $6,000,000, or $0.76 per Common Share and accompanying Common Warrant (the "Transaction"). The closing of the Transaction was subject to obtaining the approval of the Issuer's shareholders, which was obtained on January 27, 2025, and the closing of the Transaction occurred on the same date.
Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.